Pricing Log in Create free account

bioAffinity Technologies, Inc. (BIAF) vs XWELL, Inc. (XWEL)

bioAffinity Technologies, Inc. and XWELL, Inc. are both Diagnostics & Research companies. XWELL, Inc. is the larger, with a market value of $7.5M against $5.1M — 1.5× the size. XWELL, Inc. grew revenue faster over the last twelve months: −7.58% against −23.2%. XWELL, Inc. has the higher net margin (−117.8% vs −257.3%) and the higher return on invested capital (0.00% vs −408.7%). Across the 18 metrics below, XWELL, Inc. leads on 14 and bioAffinity Technologies, Inc. on 4.

Valuation

Metric BIAF XWEL Diagnostics & Research median
P/E n/m n/m 35.56
P/S 0.22 0.22 4.37
P/B 0.35 0.75 3.06
Price to free cash flow n/m n/m 35.76
EV/EBITDA 0.05 0.02 24.35
EV/Sales (0.10) (0.01) 5.51
Earnings yield (2,934.19%) (728.77%) (1.89%)
Free cash flow yield (889.05%) (217.51%) (0.15%)

Profitability

Metric BIAF XWEL Diagnostics & Research median
Gross margin 34.61% 34.34% 50.89%
Operating margin (209.82%) (61.31%) (8.57%)
Net margin (257.33%) (117.83%) (6.37%)
Free cash flow margin (195.90%) (47.65%) 0.00%
Return on equity (1,860.15%) (557.21%) (2.92%)
Return on assets (245.51%) (155.10%) (6.71%)
Return on invested capital (408.67%) 0.00% 0.00%

Growth

Metric BIAF XWEL Diagnostics & Research median
Revenue growth (TTM) (23.18%) (7.58%) 7.69%
EPS growth (last fiscal year) 61.55% (38.80%) 25.92%
Revenue growth, 5-year CAGR — 28.35% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BIAF XWEL Diagnostics & Research median
Debt to equity 0.15 0.00 0.11
Current ratio 1.44 2.27 2.02
Net debt to EBITDA 0.57 (0.08) 0.70

Dividend

Metric BIAF XWEL Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric BIAF XWEL Diagnostics & Research median
Market cap 5.08m 7.45m 2.16b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack